Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence

World Journal of Gastroenterology

Volumn 21, Issue 18, 2015, Pages 5607-5621

  Pang, Qing ^a   Zhang, Jing Yao ^a   Xu, Xin Sen ^a   Song, Si Dong ^a   Qu, Kai ^a   Chen, Wei ^a   Zhou, Yan Yan ^a   Miao, Run Chen ^a   Liu, Su Shun ^a   Dong, Ya Feng ^b   Liu, Chang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Alkaline phosphatase; Alpha fetoprotein; Aspartate aminotransferase; Blood platelets; Hepatocellular carcinoma; Recurrence

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ADULT; AGE; ARTICLE; ASCITES; BIOCHEMISTRY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION AND CHARACTERISTICS; ADVERSE EFFECTS; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AREA UNDER CURVE; ASCITES; BIOMARKERS, TUMOR; BLOOD PLATELETS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84929206633     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i18.5607     Document Type: Article

References (71)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 doi: 10.1016/S0140-6736(11)61347-0]
3. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010; 58: 273-277 [PMID: 20378277 doi: 10.1016/j.patbio.2010.01.005]
4. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol 2013; 59: 897-903 [PMID: 23714157 doi: 10.1016/j.jhep.2013.05.031]
5. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855 [PMID: 24531850 doi: 10.1136/gutjnl-2013-306627]
6. Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL, Tan SB. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108-113 [PMID: 21527845 doi: 10.1097/SLA.0b013e31821ad884]
7. Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Guo P, Hao Y, Peng BG. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol 2014; 21: 3802-3809 [PMID: 24849520 doi: 10.1245/s10434-014-3771-x]
8. Xie H, Wang H, An W, Ma W, Qi R, Yang B, Liu C, Gao Y, Xu B, Wang W. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One 2014; 9: e89081 [PMID: 24586515 doi: 10.1371/journal.pone.0089081]
9. Zhao WC, Zhang HB, Yang N, Fu Y, Qian W, Chen BD, Fan LF, Yang GS. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol 2012; 18: 3272-3281 [PMID: 22783052 DOI: 10.3748/wjg.v18.i25.3272]
10. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN. Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol 2013; 108: 416-424 [PMID: 23318478 doi: 10.1038/ajg.2012.445]
11. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012; 56: 2134-2141 [PMID: 22806754 doi: 10.1002/hep.25949]
12. Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol 2013; 19: 6834-6841 [PMID: 24187458 DOI: 10.3748/wjg.v19.i40.6834]
13. Kondo R, Yano H, Nakashima O, Tanikawa K, Nomura Y, Kage M. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C. J Gastroenterol 2013; 48: 526-534 [PMID: 22911171 doi: 10.1007/s00535-012-0656-2]
14. Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, Fleischmann E, Gruenberger B, Brostjan C, Gruenberger T. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 2014; 60: 257-266 [PMID: 24277679 doi: 10.1002/hep.26950]
15. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets 2015; 26: 199-211 [PMID: 24832135 doi: 10.3109/09537104.2014.909022]
16. Dineen SP, Roland CL, Toombs JE, Kelher M, Silliman CC, Brekken RA, Barnett CC. The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res 2009; 153: 132-137 [PMID: 18541268 doi: 10.1016/j.jss.2008.04.013]
17. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol 2014; 20: 2595-2605 [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595]
18. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM. Does this patient with liver disease have cirrhosis? JAMA 2012; 307: 832-842 [PMID: 22357834 doi: 10.1001/jama.2012.186]
19. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-921 [PMID: 17705266 doi: 10.1002/hep.21835]
20. Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T, Akarca US. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci 2007; 52: 1535-1539 [PMID: 17464564 doi: 10.1007/s10620-006-9144-y]
21. Lee S, Kim do Y. Non-invasive diagnosis of hepatitis B virusrelated cirrhosis. World J Gastroenterol 2014; 20: 445-459 [PMID: 24574713 doi: 10.3748/wjg.v20.i2.445]
22. Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 32: 679-680 [PMID: 10991637 doi: 10.1053/jhep.2000.16475]
23. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249-1253 [PMID: 10389705]
24. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194 [PMID: 24141714 doi: 10.1001/jama.2013.281053]
25. Lee IC, Chan CC, Huang YH, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e Antigen-negative Chronic Hepatitis B. J Clin Gastroenterol 2011; 45: 278-285 [PMID: 20505530 doi: 10.1097/MCG.0b013e3181dd5357]
26. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-3146 [PMID: 11721762 DOI: 10.1111/j.1572-0241.2001.05268.x]
27. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208 [PMID: 9181529]
28. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-1304 [PMID: 9260794]
29. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
30. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325 [PMID: 16729309 doi: 10.1002/hep.21178]
31. Hsieh YY, Tung SY, Lee IL, Lee K, Shen CH, Wei KL, Chang TS, Chuang CS, Wu CS, Lin YH. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J 2009; 32: 614-622 [PMID: 20035640]
32. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-292 [PMID: 15986415 doi: 10.1002/hep.20772]
33. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005; 40: 867-872 [PMID: 16109665 doi: 10.1080/0036552051001567 4]
34. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 2008; 28: 1408-1416 [PMID: 18482268 DOI: 10.1111/j.1478-3231.2008.01784.x]
35. Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One 2011; 6: e23077 [PMID: 21853071 doi: 10.1371/journal.pone.0023077]
36. Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon AH. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg 2013; 37: 820-828 [PMID: 23340708 doi: 10.1007/s00268-013-1902-3]
37. Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol 2014; 86: 131-138 [PMID: 24123090 doi: 10.1002/jmv.23790]
38. Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology 2013; 85: 153-159 [PMID: 23988857 doi: 10.1159/000354416]
39. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013; 58: 1790-1796 [PMID: 23314854 doi: 10.1007/s10620-012-2527-3]
40. Tamaki N, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol 2014; 49: 1495-1503 [PMID: 24337828 doi: 10.1007/s00535-013-0914-y]
41. Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol 2013; 59: 1135-1138 [PMID: 23742914 doi: 10.1016/j.jhep.2013.05.040]
42. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747-2760 [PMID: 22261860 doi: 10.1002/ijc.27441]
43. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98: 1161-1165 [PMID: 18349849 doi: 10.1038/sj.bjc.6604282]
44. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013; 57: 1426-1435 [PMID: 22576353 DOI: 10.1002/hep.25832]
45. Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg 2011; 15: 1173-1181 [PMID: 21512850 DOI: 10.1007/s11605-011-1538-2]
46. Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lee KC, Lin HC, Lee SD. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol 2012; 46: 789-795 [PMID: 22941428 DOI: 10.1097/MCG.0b013e31825ceeb5]
47. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 2012; 46: 62-70 [PMID: 21934530 doi: 10.1097/MCG.0b013e31822b36cc]
48. Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D, Gates VL, Habib A, Mulcahy MF, Salem R. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol 2014; 25: 1056-1066 [PMID: 24613269 doi: 10.1016/j.jvir.2014.01.010]
49. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014; 9: e90929 [PMID: 24603710 doi: 10.1371/journal.pone.0090929]
50. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418 [PMID: 15710992 doi: 10.1136/gut.2004.048124]
51. Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol 2006; 21: 588-594 [PMID: 16638104 DOI: 10.1111/j.1440-1746.2005.04127.x]
52. Kobayashi T, Itamoto T, Tashiro H, Amano H, Oshita A, Tanimoto Y, Kuroda S, Tazawa H, Ohdan H. Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. J Hepatobiliary Pancreat Sci 2011; 18: 689-699 [PMID: 21445633 doi: 10.1007/s00534-011-0379-4]
53. Seo JY, Kim W, Kwon JH, Jin EH, Yu SJ, Kim HY, Jung YJ, Kim D, Kim YJ, Yoon JH, Lee HS. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver Int 2013; 33: 884-893 [PMID: 23461618 doi: 10.1111/liv.12132]
54. Park LS, Tate JP, Justice AC, Lo Re V, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 2011; 20: 2512-2517 [PMID: 22028407 DOI: 10.1158/1055-9965.EPI-11-0582]
55. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-9.e4 [PMID: 23860502 doi: 10.1053/j.gastro.2013.06.057]
56. Choi SB, Kim HJ, Song TJ, Ahn HS, Choi SY. Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 2014; 21: 639-647 [PMID: 24867654 doi: 10.1002/jhbp.124]
57. Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T, Shirabe K, Shimada M, Maehara Y. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg 2007; 204: 580-587 [PMID: 17382216 doi: 10.1016/j.jamcollsurg.2007.01.0 35]
58. Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC, McMasters KM, Cho CS, Winslow ER, Wood WC, Staley CA. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg 2011; 212: 638-648; discussion 648-650 [PMID: 21463803 doi: 10.1016/j.jamcollsurg. 2011.01.004]
59. Lee HS, Park SY, Kim SK, Kweon YO, Tak WY, Cho CM, Jeon SW, Jung MK, Park HG, Lee DW, Choi SY. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol 2012; 18: 302-308 [PMID: 23091811 DOI: 10.3350/cmh.2012.18.3.302]
60. Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K, Hirohashi K. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res 2004; 30: 221-225 [PMID: 15589130 doi: 10.1016/j.hepres.2004.10.005]
61. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22: 669-675 [PMID: 17444854 doi: 10.1111/j.1440-1746.2007.04898.x]
62. Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol 2012; 13: 49-53 [PMID: 22980591 doi: 10.1016/j.ajg.2012.06.004]
63. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006; 44: 1518-1527 [PMID: 17133456]
64. Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol 2008; 23: 453-458 [PMID: 17725599 doi: 10.1111/j.1440-1746.2007.05120. x]
65. Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford) 2012; 14: 741-745 [PMID: 23043662 doi: 10.1111/j.1477-2574.2012.00507.x]
66. Carr BI, Cavallini A, D'Alessandro R, Refolo MG, Lippolis C, Mazzocca A, Messa C. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 2014; 14: 43 [PMID: 24468103 DOI: 10.1186/1471-2407-14-43]
67. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122: 2011-2018 [PMID: 23908470 doi: 10.1182/blood-2013-04-460147]
68. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-1382 [PMID: 15915455 doi: 10.1002/hep.20717]
69. Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol 2006; 40: 521-527 [PMID: 16825935]
70. Calés P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourliére M, de Muret A, Sturm N, Hunault G, Oberti F. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-1362 [PMID: 18492022 doi: 10.1111/j.1478-3231.2008.01789.x]
71. Kayadibi H, Yasar B, Ozkara S, Serdar MA, Kurdas OO, Gonen C. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis. Scand J Clin Lab Invest 2014; 74: 240-247 [PMID: 24460024 doi: 10.3109/00365513.2013.879392]